Femasys Inc. (FEMY)
- Previous Close
1.3300 - Open
1.3204 - Bid 1.2600 x 500
- Ask 1.3000 x 300
- Day's Range
1.2108 - 1.3643 - 52 Week Range
0.2480 - 4.7500 - Volume
136,817 - Avg. Volume
733,153 - Market Cap (intraday)
28.066M - Beta (5Y Monthly) -2.99
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.75
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
www.femasys.comRecent News: FEMY
Performance Overview: FEMY
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FEMY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FEMY
Valuation Measures
Market Cap
28.07M
Enterprise Value
13.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.23
Price/Book (mrq)
1.53
Enterprise Value/Revenue
12.17
Enterprise Value/EBITDA
-0.99
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.62%
Return on Equity (ttm)
-84.82%
Revenue (ttm)
1.07M
Net Income Avi to Common (ttm)
-14.25M
Diluted EPS (ttm)
-0.9300
Balance Sheet and Cash Flow
Total Cash (mrq)
21.72M
Total Debt/Equity (mrq)
36.51%
Levered Free Cash Flow (ttm)
-6.28M